Literature DB >> 34206967

Development of a Cyclodextrin-Based Mucoadhesive-Thermosensitive In Situ Gel for Clonazepam Intranasal Delivery.

Marzia Cirri1, Francesca Maestrelli1, Giulia Nerli1, Natascia Mennini1, Mario D'Ambrosio2, Cristina Luceri2, Paola Angela Mura1.   

Abstract

A thermosensitive, mucoadhesive in-situ gel for clonazepam (CLZ) intranasal delivery was developed, which aimed to achieve prolonged in-situ residence and controlled drug release, overcoming problems associated with its oral or parenteral administration. Poloxamer was selected as a thermosensitive polymer and chitosan glutamate and sodium hyaluronate as mucoadhesive and permeation enhancer. Moreover, randomly methylated β-Cyclodextrin (RAMEB) was used to improve the low drug solubility. A screening DoE was applied for a systematic examination of the effect of varying the formulation components proportions on gelation temperature, gelation time and pH. Drug-loaded gels at different clonazepam-RAMEB concentrations were then prepared and characterized for gelation temperature, gelation time, gel strength, mucoadhesive strength, mucoadhesion time, and drug release properties. All formulations showed suitable gelation temperature (29-30.5 °C) and time (50-65 s), but the one with the highest drug-RAMEB concentration showed the best mucoadhesive strength, longest mucoadhesion time (6 h), and greatest release rate. Therefore, it was selected for cytotoxicity and permeation studies through Caco-2 cells, compared with an analogous formulation without RAMEB and a drug solution. Both gels were significantly more effective than the solution. However, RAMEB was essential not only to promote drug release, but also to reduce drug cytotoxicity and further improve its permeability.

Entities:  

Keywords:  clonazepam; cytotoxicity; in situ nasal gel; mucoadhesive polymers; permeability; poloxamer; randomly methylated β-Cyclodextrin

Year:  2021        PMID: 34206967     DOI: 10.3390/pharmaceutics13070969

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  40 in total

Review 1.  A review of intranasal formulations for the treatment of seizure emergencies.

Authors:  Mamta Kapoor; James C Cloyd; Ronald A Siegel
Journal:  J Control Release       Date:  2016-07-07       Impact factor: 9.776

Review 2.  A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

Authors:  Gilles Dumortier; Jean Louis Grossiord; Florence Agnely; Jean Claude Chaumeil
Journal:  Pharm Res       Date:  2006-11-11       Impact factor: 4.200

3.  Updates on thermosensitive hydrogel for nasal, ocular and cutaneous delivery.

Authors:  Qianwen Wang; Zhong Zuo; Cheuk Kit Chucky Cheung; Sharon Shui Yee Leung
Journal:  Int J Pharm       Date:  2019-01-21       Impact factor: 5.875

Review 4.  In situ gelling and mucoadhesive polymers: why do they need each other?

Authors:  Forouhe Zahir-Jouzdani; Julian Dominik Wolf; Fatemeh Atyabi; Andreas Bernkop-Schnürch
Journal:  Expert Opin Drug Deliv       Date:  2018-09-07       Impact factor: 6.648

5.  Prediction of Permeation and Cellular Transport of Silybum marianum Extract Formulated in a Nanoemulsion by Using PAMPA and Caco-2 Cell Models.

Authors:  Vieri Piazzini; Chiara Rosseti; Elisabetta Bigagli; Cristina Luceri; Anna Rita Bilia; Maria Camilla Bergonzi
Journal:  Planta Med       Date:  2017-05-04       Impact factor: 3.352

6.  A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery.

Authors:  Taís Gratieri; Guilherme Martins Gelfuso; Eduardo Melani Rocha; Victor Hugo Sarmento; Osvaldo de Freitas; Renata Fonseca Vianna Lopez
Journal:  Eur J Pharm Biopharm       Date:  2010-02-25       Impact factor: 5.571

7.  Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride.

Authors:  Hyun-Jong Cho; Prabagar Balakrishnan; Eun-Kyoung Park; Ki-Won Song; Soon-Sun Hong; Tae-Young Jang; Kyu-Sung Kim; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  J Pharm Sci       Date:  2010-08-27       Impact factor: 3.534

8.  Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat.

Authors:  Hartwig Wolburg; Karen Wolburg-Buchholz; Heike Sam; Sándor Horvát; Maria A Deli; Andreas F Mack
Journal:  Histochem Cell Biol       Date:  2008-03-14       Impact factor: 4.304

Review 9.  Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs.

Authors:  E Marttin; J C Verhoef; F W Merkus
Journal:  J Drug Target       Date:  1998       Impact factor: 5.121

10.  Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats.

Authors:  Shagufta Khan; Kundan Patil; Nishan Bobade; Pramod Yeole; Rajiv Gaikwad
Journal:  J Drug Target       Date:  2010-04       Impact factor: 5.121

View more
  3 in total

1.  Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation.

Authors:  Rehab Abdelmonem; Inas Essam Ibrahim Al-Samadi; Rasha M El Nashar; Bhaskara R Jasti; Mohamed A El-Nabarawi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

2.  Preparation, Characterization and Evaluation of the Anti-Inflammatory Activity of Epichlorohydrin-β-Cyclodextrin/Curcumin Binary Systems Embedded in a Pluronic®/Hyaluronate Hydrogel.

Authors:  Ana-María Fernández-Romero; Francesca Maestrelli; Sara García-Gil; Elena Talero; Paola Mura; Antonio M Rabasco; María Luisa González-Rodríguez
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

3.  Optimization of the Micellar-Based In Situ Gelling Systems Posaconazole with Quality by Design (QbD) Approach and Characterization by In Vitro Studies.

Authors:  Meltem Ezgi Durgun; Burcu Mesut; Mayram Hacıoğlu; Sevgi Güngör; Yıldız Özsoy
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.